Roy Galvin - Nov 1, 2022 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
President, Global Plasma & BC
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Galvin
Stock symbol
HAE
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/3/2022, 04:54 PM
Previous filing
Oct 17, 2022
Next filing
May 17, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +2.38K 2.38K Nov 1, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +5.26K $0.00 5.26K Nov 1, 2022 Common Stock 5.26K $83.96 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.